[go: up one dir, main page]

DK2344198T3 - Lipidbaserede farmaceutiske præparater til topisk anvendelse - Google Patents

Lipidbaserede farmaceutiske præparater til topisk anvendelse Download PDF

Info

Publication number
DK2344198T3
DK2344198T3 DK09816940.2T DK09816940T DK2344198T3 DK 2344198 T3 DK2344198 T3 DK 2344198T3 DK 09816940 T DK09816940 T DK 09816940T DK 2344198 T3 DK2344198 T3 DK 2344198T3
Authority
DK
Denmark
Prior art keywords
lipid
pharmaceutical preparations
based pharmaceutical
topic use
topic
Prior art date
Application number
DK09816940.2T
Other languages
English (en)
Inventor
Shoukath M Ali
Ateeq Ahamd
Moghis U Ahmad
Saifuddin Sheikh
Imran Ahmad
Original Assignee
Jina Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42060413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2344198(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jina Pharmaceuticals Inc filed Critical Jina Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2344198T3 publication Critical patent/DK2344198T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
DK09816940.2T 2008-09-27 2009-09-25 Lipidbaserede farmaceutiske præparater til topisk anvendelse DK2344198T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10071408P 2008-09-27 2008-09-27
PCT/US2009/058463 WO2010036947A2 (en) 2008-09-27 2009-09-25 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof

Publications (1)

Publication Number Publication Date
DK2344198T3 true DK2344198T3 (da) 2020-11-30

Family

ID=42060413

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09816940.2T DK2344198T3 (da) 2008-09-27 2009-09-25 Lipidbaserede farmaceutiske præparater til topisk anvendelse

Country Status (15)

Country Link
US (1) US9750812B2 (da)
EP (1) EP2344198B1 (da)
JP (3) JP2012504135A (da)
CA (1) CA2737025C (da)
CY (1) CY1123579T1 (da)
DK (1) DK2344198T3 (da)
ES (1) ES2834006T3 (da)
HR (1) HRP20201860T1 (da)
HU (1) HUE052571T2 (da)
LT (1) LT2344198T (da)
MX (1) MX2011003207A (da)
PL (1) PL2344198T3 (da)
PT (1) PT2344198T (da)
SI (1) SI2344198T1 (da)
WO (1) WO2010036947A2 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006442A1 (en) 2008-07-18 2010-01-21 Biomod Inc. Articles of manufacture releasing an active ingredient
US10633688B2 (en) 2010-09-24 2020-04-28 Follea International Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
US9588118B2 (en) 2010-09-24 2017-03-07 Follea International Devices for performing colorimetric assay with plucked human hair
US8691518B2 (en) 2010-09-24 2014-04-08 Global Life Science Partners Limited Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
ITMI20102165A1 (it) * 2010-11-23 2012-05-24 Medichem Srl Composizione per il lavaggio dei capelli e del cuoio capelluto
JP5934781B2 (ja) * 2011-04-25 2016-06-15 パーク、ジュン−ヒョン 脱毛防止及び発毛促進用外用剤組成物
CN104394850A (zh) * 2012-02-16 2015-03-04 布莱特赛德创新有限公司 膳食和营养组合物及应用的方法
WO2013160896A1 (en) * 2012-04-25 2013-10-31 Hadasit Medical Research Services And Development Ltd. Pomegranate oil for preventing and treating neurodegenerative diseases
BR102012022034B1 (pt) * 2012-08-31 2020-02-18 Biolab Sanus Farmacêutica Ltda. Nanopartícula polimérica de finasterida, suspensão aquosa contendo a mesma, composição para tratamento de alopecia, processo de preparação de dita composição, e seu uso
BR102012022036B1 (pt) 2012-08-31 2019-10-01 Biolab Sanus Farmacêutica Ltda. Nanopartícula polimérica de finasterida e minoxidil, processo de sua preparação, suspensão aquosa contendo a mesma, composição farmacêutica, e seu uso
WO2014078929A1 (pt) * 2012-11-26 2014-05-30 Universidade Federal De Minas Gerais - Ufmg Formulações tópicas para a prevenção e tratamento da alopecia e para inibição do crescimento de pêlos
ES2985790T3 (es) * 2013-05-03 2024-11-07 Emollivet Ab Composición tópica y portador para la administración de principios activos farmacéuticos o cosméticos
WO2015023926A1 (en) 2013-08-15 2015-02-19 Mary Kay Inc. Topical skin compositions for treating wrinkles
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
US11660344B2 (en) 2013-11-17 2023-05-30 Medrx Co., Ltd. Transdermal colloidal solution agent
ES2831319T3 (es) * 2013-11-17 2021-06-08 Medrx Co Ltd Formulación líquida coloidal absorbente transdérmica
EP3626244B1 (en) * 2014-10-29 2023-06-07 Samson Clinical Pty Ltd. Oral minoxidil for the treatment of alopecia areata
ES2765277T3 (es) 2014-12-22 2020-06-08 Reactive Reality Gmbh Método y sistema para generar datos de modelo de prenda
US11298318B2 (en) * 2015-04-13 2022-04-12 Fountain Technologies International, Llc One-step method for production of ultra-small lipid structures
EP3299012A4 (en) * 2015-05-19 2018-12-26 MEDRx Co., Ltd. Transdermal liquid preparation
JP7186093B2 (ja) 2016-04-19 2022-12-08 ナンヤン テクノロジカル ユニヴァーシティー 前眼部疾患の治療のためのタクロリムスの持続送達用ナノリポソーム
LT3532067T (lt) 2016-10-28 2022-08-25 Les Laboratoires Servier Liposominė vaisto forma, skirta naudoti gydant vėžį
EP3630176A1 (en) * 2017-05-30 2020-04-08 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
KR20240064747A (ko) * 2017-07-12 2024-05-13 삼손 클리니컬 피티와이 엘티디 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료
PT3977983T (pt) * 2017-10-27 2025-02-27 Xyon Health Inc Formulações tópicas para tratar distúrbios dermatológicos incluindo calvíce de padrão masculino
MX390288B (es) * 2018-02-06 2025-03-20 Centro Int De Cosmiatria S A P I De C V Formulación y método para el tratamiento de la alopecia androgénica.
US11311529B2 (en) 2018-11-08 2022-04-26 Varsona Therapeutics, Inc. Topical formulations of 5-α-reductase inhibitors and uses thereof
WO2020109365A1 (en) * 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
EP4149412A4 (en) * 2020-05-12 2024-08-28 Chemistryrx COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
US11850300B2 (en) 2022-03-17 2023-12-26 Rally Guide Topical lotion composition, methods of use, and methods of preparation
AU2024250062A1 (en) * 2023-04-14 2025-10-23 Beijing Jitai Pharmaceutical Technology Co., Ltd. Lipid nanoparticle compositions and uses thereof
WO2025037276A1 (en) * 2023-08-16 2025-02-20 Jina Pharmaceuticals Inc. COMPOSITIONS CONTAINING mTOR INHIBITORS AND LIPIDS

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3585967D1 (de) * 1984-03-08 1992-06-11 Phares Pharma Holland Liposombildende zusammensetzung.
US4663167A (en) * 1984-04-16 1987-05-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
US4897269A (en) * 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
EP0177223B1 (en) 1984-09-24 1990-02-28 Michael Mezei Pharmaceutical multi-phase composition
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
US6406713B1 (en) * 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5030442A (en) * 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US4828837A (en) * 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
DE3888994T2 (de) 1987-04-03 1994-11-03 Merck & Co Inc Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
CA1330199C (en) * 1987-12-22 1994-06-14 Thomas D. Madden Spontaneous vesiculation of multilamellar liposomes
US5000887A (en) * 1988-05-17 1991-03-19 Liposome Technology, Inc. Preparation of uniform-size liposomes
AU638245B2 (en) 1989-03-31 1993-06-24 Regents Of The University Of California, The Preparation of liposome and lipid complex compositions
WO1992003123A1 (en) * 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
US20040175417A1 (en) * 1990-10-19 2004-09-09 Gilead Sciences, Inc. Amphotericin B liposome preparation
GB9111611D0 (en) 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
US6733776B1 (en) * 1992-04-02 2004-05-11 Anticancer, Inc. Method for promoting hair growth
US7556825B2 (en) * 1993-04-02 2009-07-07 Anticancer, Inc. Method for promoting hair growth
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
FI100692B (fi) * 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US6001812A (en) * 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
JPH0971513A (ja) 1995-09-07 1997-03-18 Taisho Pharmaceut Co Ltd 育毛剤
US5834014A (en) 1995-10-06 1998-11-10 The Regents Of The University Of Michigan Stimulation of hair follicles
JP3596835B2 (ja) 1996-08-13 2004-12-02 株式会社ノエビア 養毛剤
US6030948A (en) * 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
US6265412B1 (en) 1998-05-26 2001-07-24 Taisho Pharmaceutical Co., Ltd. Minoxidil compositions for external use
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
JP4444385B2 (ja) * 1999-02-25 2010-03-31 帝人株式会社 リポソーム用時調製用キット
NZ514046A (en) * 1999-03-11 2003-10-31 Fujisawa Pharmaceutical Co Liposome preparations
CA2309373A1 (en) * 1999-05-27 2000-11-27 Johnson & Johnson Consumer Companies, Inc. Novel topical formulations
US6596266B2 (en) * 2000-02-18 2003-07-22 Natural Science, Inc. Compositions containing minoxidil and saw palmetto for treating baldness
JP4780429B2 (ja) 2000-04-07 2011-09-28 大正製薬株式会社 ミノキシジル含有製剤
CA2408152A1 (en) 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
IN188843B (da) * 2000-06-22 2002-11-09 Vinod Daftary Gautam Dr
WO2002007728A1 (en) 2000-07-19 2002-01-31 Knowles W Roy Hair loss prevention
DE10036799A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Neues Mittel zur Behandlung der Haare und der Kopfhaut
SE0100374D0 (sv) * 2001-02-07 2001-02-07 Pharmacia Ab Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof
CA2442539C (en) * 2001-03-27 2011-11-08 Phares Pharmaceutical Research N.V. Method and composition for solubilising a biologically active compound with low water solubility
JP4796260B2 (ja) 2001-04-05 2011-10-19 大正製薬株式会社 ミノキシジル含有製剤
US7045550B2 (en) * 2001-08-07 2006-05-16 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
AU2003270102B2 (en) * 2002-08-23 2008-10-02 Medigene Ag Non-vesicular cationic lipid formulations
MXPA05003616A (es) * 2002-10-03 2006-01-24 Univ Mississippi Composiciones que comprenden anfotericina b altamente purificada.
AU2003268478A1 (en) * 2002-10-16 2004-05-25 Neopharm, Inc. Cardiolipin molecules and method of synthesis
JP2004155690A (ja) * 2002-11-05 2004-06-03 Shiseido Co Ltd 養毛剤組成物
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
KR100508019B1 (ko) * 2003-07-19 2005-08-17 한미약품 주식회사 고순도 1-안드로스텐 유도체의 제조 방법
ITMI20032019A1 (it) * 2003-10-17 2005-04-18 Fidia Farmaceutici Microemulsioni di retinoidi e composizioni farmaceutiche che le contengono
AU2005245018A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
AU2005279771A1 (en) * 2004-08-30 2006-03-09 Theregen, Inc Cultured three dimensional tissues and uses thereof
MX2007003789A (es) 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
BRPI0609504A2 (pt) * 2005-03-30 2010-04-13 Wyeth Corp métodos para estimular o crescimento capilar administrando proteìnas morfogenéticas ósseas (bmps)
JP2006290841A (ja) * 2005-04-14 2006-10-26 Nippon Zettoc Co Ltd 化粧料の製造方法および化粧料
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
WO2008038140A2 (en) * 2006-06-07 2008-04-03 Foamix Ltd. Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof
ES2617747T3 (es) * 2006-10-10 2017-06-19 Jina Pharmaceuticals Inc. Sistemas acuosos para la preparación de compuestos farmacéuticos basados en lípidos; composiciones, procedimientos y usos de los mismos
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
CN101559038B (zh) 2009-05-21 2011-03-16 江苏黄河药业股份有限公司 非那雄胺的固体脂质纳米粒及其制备方法

Also Published As

Publication number Publication date
JP2014221784A (ja) 2014-11-27
HRP20201860T1 (hr) 2021-04-16
US9750812B2 (en) 2017-09-05
SI2344198T1 (sl) 2021-01-29
WO2010036947A2 (en) 2010-04-01
ES2834006T3 (es) 2021-06-16
EP2344198A2 (en) 2011-07-20
JP6196943B2 (ja) 2017-09-13
US20110212167A1 (en) 2011-09-01
PT2344198T (pt) 2020-12-04
LT2344198T (lt) 2021-02-25
MX2011003207A (es) 2011-11-04
PL2344198T3 (pl) 2021-05-31
CA2737025C (en) 2012-09-04
WO2010036947A3 (en) 2010-06-10
HUE052571T2 (hu) 2021-05-28
CA2737025A1 (en) 2010-04-01
EP2344198A4 (en) 2013-01-09
EP2344198B1 (en) 2020-11-04
CY1123579T1 (el) 2022-03-24
JP2017048188A (ja) 2017-03-09
JP2012504135A (ja) 2012-02-16

Similar Documents

Publication Publication Date Title
DK2344198T3 (da) Lipidbaserede farmaceutiske præparater til topisk anvendelse
HUE062860T2 (hu) Magas koncentrációjú gyógyszerészeti készítmények
BRPI0821474A2 (pt) formulação farmacêutica líquida estável
DK2238985T4 (da) Højkoncentreret antistofholdig væskeformulering
DK3072906T3 (da) Antistofformulering
EP2358392A4 (en) ANTIBODY FORMULATION
BRPI1006519A2 (pt) formulação de anticorpos
SMT201400069B (it) Formulazione farmaceutica
DK2658541T3 (da) Topisk lokaliseret isoxazolinformulering omfattende glycofurol
DK2234600T3 (da) Antistofformulering
DK2274032T3 (da) Anordning til medicinindgivelse
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI0920521A2 (pt) combinação farmacêutica
DK2493533T3 (da) Automatisk applikator til flydende farmaceutiske præparater, fortrinsvist særligt til insulin
BRPI1004940A2 (pt) composição farmacêutica
BRPI0921654A2 (pt) formulação farmacêutica
BRPI1015939A2 (pt) composição farmacêutica
HUE047767T2 (hu) Macitentánt tartalmazó terápiás készítmények
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI1005433A2 (pt) preparações farmacêuticas transdérmicas
DK2391351T3 (da) Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
BRPI0921313A2 (pt) composição farmaucêutica
DK2271618T3 (da) Farmaceutiske forbindelser
BR112012003149A2 (pt) composição farmacêutica